当前位置: X-MOL 学术ACS Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Next Wave of Influenza Drugs
ACS Infectious Diseases ( IF 5.3 ) Pub Date : 2017-09-11 00:00:00 , DOI: 10.1021/acsinfecdis.7b00142
Megan L. Shaw 1
Affiliation  

Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients.

中文翻译:

下一波流感药物

目前,用于流感治疗的选择仅限于一类药物神经氨酸酶抑制剂。在对耐药性的担忧中,人们已经在发现具有不同靶标和作用机制的新药物上付出了很多努力,并取得了巨大的成功。现在有几个候选药物处于晚期开发阶段,包括靶向病毒聚合酶复合物三个亚基的小分子和靶向血凝素的单克隆抗体,以及针对宿主的疗法。现在,具有多种机制的药物的可用性为探索用于流感的组合疗法打开了大门,并且给药途径的范围为治疗住院患者提供了更多的机会。
更新日期:2017-09-11
down
wechat
bug